1454846-35-5
- Product Name：Loratinib
- Molecular Formula：
- Purity：99%
- Molecular Weight：406.419
Product Details;
CasNo： 1454846-35-5
Top Quality Chinese Manufacturer supply 1454846-35-5 Loratinib We supply high quality PF-06463922 (CAS 1454846-35-5), in stock, factory directly supply to clients, lower prices, more competitiveness.
What is the PF-06463922 ?
PF-06463922 is , while it's Molecular Formula is C21H19FN6O2. PF- 06463922 is a potent and selective ROS1/ALK inhibitor capable to block crizotinib-resistant ROS1 mutations. Used in the treatment of human cancers.
What is the CAS number for PF-06463922 ?
The CAS number of PF-06463922 is 1454846-35-5.
More information of PF-06463922 1454846-35-5 are:
|
CAS Number |
1454846-35-5 |
|
Molecular Formula |
C21H19FN6O2 |
|
Molecular Weight |
406.419 |
|
Density |
1.42±0.1 g/cm3(Predicted) |
|
Melting Point |
184-187°C |
|
Boiling Point |
675.0±55.0 °C(Predicted) |
|
Pka |
6.05±0.40(Predicted) |
What is PF-06463922 (1454846-35-5) used for?
Lorlatinib (PF-06463922) is a new drug under development for the sub-group of advanced non-small cell lung cancerwho are ALK or ROS1 positive and have already undergone gene treatment with drugs thatspecifically targetthis type of cancer.Lorlatinib is currently being evaluated in phase II clinical trials as an oral dose at 100 mg daily. If marketed it will becomean additional targeted treatment for this sub-group of ALKor ROS1 positive patients. Lorlatinib acts by inhibiting the ALK and ROS1 receptor tyrosine kinases, with potent activity against a broad spectrum of ALK resistant mutations. By inhibiting ALK phosphorylation and ROS1 activity, lorlatinib inhibits the downstream signalling, thereby inducing the apoptosis process, which results in the inhibition of tumour cells proliferation. Due to tumor complexity and development of resistance to treatment, disease progression is a challenge in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). A common site for progression in metastatic NSCLC is the brain. Lorlatinib was specifically designed to inhibit tumor mutations that drive resistance to other ALK inhibitors and to penetrate the blood brain barrier.
Articles related to PF-06463922:
|
Article |
Source |
|
Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners |
Elleraas, Jeff,Ewanicki, Jason,Johnson, Ted W.,Sach, Neal W.,Collins, Michael R.,Richardson, Paul F. , p. 3590 - 3595 (2016) |
|
CRYSTALLINE LORLATINIB : FUMARIC ACID AND SOLID STATE FORM THEREOF |
- Paragraph 00114, (2021/02/12) |
How to get the best price on PF-06463922?
Golden Pharma Co., Limited is a quality supplier and manufacturer of PF-06463922 . You can buy high quality, low price PF-06463922 1454846-35-5 here. Contact us.
Relevant Products
-
IdebenoneCAS：58186-27-9
-
IfosfamideCAS：3778-73-2
-
Polyethylene Glycol
CAS：25322-68-3
-
AtogepantCAS：1374248-81-3
